Publications by authors named "N van der Burg-de Graauw"
Article Synopsis
- The IMWG frailty index shows that frailty levels in patients undergoing anti-myeloma treatment can change frequently over time.
- Assessing frailty dynamically during treatment provides better predictions for survival and early mortality than just looking at initial frailty levels.
- The study references two clinical trials, HOVON 143 (NTR6297) and HOVON 123 (NTR4244), related to this research.
Background: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and intermediate-fit MM patients during active treatment and post-treatment follow-up are absent.
Methods: The HOVON123 study (NTR4244) was a phase II trial in which NDMM patients ≥ 75 years were treated with nine dose-adjusted cycles of Melphalan-Prednisone-Bortezomib (MPV).
Purpose: Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex).
Methods: Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years.
The paracondylar process: an unusual and treatable cause of posttraumatic headache.
Spine (Phila Pa 1976)
April 2008
Study Design: Case report and clinical discussion.
Objective: To describe a case of persistent posttraumatic headache associated with the presence of a paracondylar process, and the result of surgical resection of this osseous anomaly.
Summary Of Background Data: The paracondylar process is one of a group of congenital anomalies of the craniovertebral junction.